p53 amyloid aggregation in cancer: function, mechanism, and therapy
Open Access
- 28 September 2022
- journal article
- review article
- Published by Springer Nature in Experimental Hematology & Oncology
- Vol. 11 (1) , 1-13
Abstract
Similar to neurodegenerative diseases, the concept that tumors are prion like diseases has been proposed in recent years. p53, the most well-known tumor suppressor, has been extensively studied for its expression, mutation, and function in various tumors. Currently, an interesting phenomenon of p53 prion-like aggregation has been found in several tumors, and studies have found that its pathological aggregation may lead to functional alterations and ultimately affect tumor progression. It has been demonstrated that the mechanism of p53 aggregation involves its mutation, domains, isoform, etc. In addition to p53 itself, some other factors, including Zn2+ concentration, pH, temperature and chaperone abnormalities, can also contribute to p53 aggregation. Although there are some studies about the mechanism and role of p53 aggregation and amyloidosis in tumors, there still exist some controversies. In this paper, we review the mechanism of p53 amyloid fibril structure and discuss the characteristics and effects of p53 amyloid aggregation, as well as the pathogenic mechanism leading to the occurrence of aggregation in tumors. Finally, we summarize the various inhibitors targeting p53 aggregation and prion-like behavior. In conclusion, a comprehensive understanding of p53 aggregation can expand our understanding of the causes leading its loss of physiological function and that targeting p53 aggregation might be a promising therapeutic strategy for tumor therapy.Keywords
Funding Information
- National Natural Science Foundation of China (81502542, 81570537, 81974074 and 82172654)
- Department of Science and Technology of Hunan Province (2018RS3026 and 2021RC4012)
This publication has 123 references indexed in Scilit:
- Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressorBioscience Reports, 2013
- First-order rate-determining aggregation mechanism of p53 and its implicationsProceedings of the National Academy of Sciences, 2012
- Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibitionProceedings of the National Academy of Sciences, 2012
- Mutant p53 Aggregates into Prion-like Amyloid Oligomers and FibrilsJournal of Biological Chemistry, 2012
- Transmissible Proteins: Expanding the Prion HeresyCell, 2012
- Amyloid fibers provide structural integrity to Bacillus subtilis biofilmsProceedings of the National Academy of Sciences, 2010
- The p53 Core Domain Is a Molten Globule at Low pHJournal of Biological Chemistry, 2010
- Ligand Binding and Hydration in Protein Misfolding: Insights from Studies of Prion and p53 Tumor Suppressor ProteinsAccounts of Chemical Research, 2009
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- Rationalization of the effects of mutations on peptide andprotein aggregation ratesNature, 2003